A theragnostic system with multifunctional benefits is presented. This system promprises  a near-infrared mediated quantum dots and paclitaxel co-loaded nanostructered lipid carrier. Quantum dots are known to possess unique properties that make them ideal for imaging purpose and that they may be used for cancer detection. For several decades, paclitaxel has been the most effective drug against a wide range of solid tumours. Theragnostic nanomedicine provides a platform to monitor, evaluate, and individualize treatment in real-time. Evaluation of cancer treatment outcome at an early-stage therapy is key to increase survival prospects of a patient. Previously, a novel co-loaded nanostructured lipid carriers’ theragnostic system for parenteral administration was developed. The aim of this study was to further investigate the co-loaded nanostructured lipid carriers in order to provide interpretation necessary for preclinical elucidation of the formulation, in part. The co-loaded nanostructured lipid carriers were prepared by oil/water emulsification-solvent evaporation technique. In this study, stability and co-loaded nanostructured lipid carriers’ internalization by MCF 7 and HepG2 cells were investigated. The co-loaded nanostructured lipid carriers were stable at 4C for 1 month. The formulation was successfully internalized by MCF-7 and HepG2 cells. Nevertheless, the co-loaded nanostructured lipid carrier was more apt for MCF-7 cells. This finding affirms the formulation to be the most appropriate for breast cancer treatment. In addition, if taken correctly by a patient for a month, the formulation would give true reflection of the contents’ amounts, the factor paramount to appropriate changes in treatment protocol. It can therefore safely be concluded that the co-loaded nanostructured lipid carrier formulation may be potentially an effective theragnostic translational system.

Dr Livesey D. Olerile is a seasoned Scientist who has published several articles in reputable  international journals. Dr Olerile is serving as an Editorial Review Board member for Technology in Cancer Research & Treatment Journal. He holds a patent (Method and Formulation for Inhalation) which has been granted worldwide. In real-time, this patent is associated with Monash University project of Developing Oxytocin Dry Powder Inhaler for postpartum haemorrhage prevention and treatment in developing countries, which completed Phase 2 of clinical trials under the auspices of GlaxoSmithKline and USA healthcare giant, Johnson and Johnson. Dr Olerile is currently residing in Gaborone, Botswana where he is working as a consultant.